Non-neovascular age-related macular degeneration with subretinal fluid.
Angiogenesis Inhibitors
/ therapeutic use
Fluorescein Angiography
Follow-Up Studies
Humans
Intravitreal Injections
Macular Degeneration
/ drug therapy
Retinal Detachment
/ diagnosis
Retinal Drusen
/ diagnosis
Retinal Pigments
/ therapeutic use
Retrospective Studies
Subretinal Fluid
/ diagnostic imaging
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
Visual Acuity
Wet Macular Degeneration
/ diagnosis
Angiogenesis
Choroid
Degeneration
Macula
Retina
Journal
The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
25
06
2020
accepted:
13
08
2020
revised:
05
08
2020
pubmed:
14
9
2020
medline:
3
3
2022
entrez:
13
9
2020
Statut:
ppublish
Résumé
To evaluate the various patterns of subretinal fluid (SRF) in eyes with age-related macular degeneration (AMD) in the absence of macular neovascularisation (MNV) and to assess the long-term outcomes in these eyes. This retrospective study included only eyes with non-neovascular AMD and associated SRF. Eyes with evidence of MNV were excluded. Spectral-domain optical coherence tomography (SD-OCT) was obtained at baseline and at follow-up, and qualitative and quantitative SD-OCT analysis of macular drusen including drusenoid pigment epithelial detachment (PED) and associated SRF was performed to determine anatomic outcomes. Forty-five eyes (45 patients) were included in this analysis. Mean duration of follow-up was 49.7±36.7 months. SRF exhibited three different morphologies: crest of fluid over the apex of the drusenoid PED, pocket of fluid at the angle of a large druse or in the crypt of confluent drusen or drape of low-lying fluid over confluent drusen. Twenty-seven (60%) of the 45 eyes with fluid displayed collapse of the associated druse or drusenoid PED and 24 (53%) of the 45 eyes developed evidence of complete or incomplete retinal pigment epithelial and outer retinal atrophy. Non-neovascular AMD with SRF is an important clinical entity to recognise to avoid unnecessary anti-vascular endothelial growth factor therapy. Clinicians should be aware that SRF can be associated with drusen or drusenoid PED in the absence of MNV and may be the result of retinal pigment epithelial (RPE) decompensation and RPE pump failure.
Identifiants
pubmed: 32920528
pii: bjophthalmol-2020-317326
doi: 10.1136/bjophthalmol-2020-317326
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Retinal Pigments
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1420Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.